The core pharmaceutical business continued to grow, and the Company launched its product in new markets.
On the manufacturing side, yield was improved to further strengthen the competitive advantage in manu
The core pharmaceutical business continued to grow, and the Company launched its product in new markets.
On the manufacturing side, yield was improved to further strengthen the competitive advantage in manu
1st Jan change | Capi. | |
---|---|---|
+29.77% | 49.46B | |
+1.00% | 42.58B | |
+49.62% | 42.49B | |
-5.26% | 29.09B | |
+13.68% | 26.61B | |
-22.99% | 18.64B | |
+8.22% | 13.16B | |
+32.41% | 12.55B | |
+24.01% | 12.1B |